Modulation of Tau Pathology in Alzheimer’s Disease by Dietary Bioactive Compounds
Tau is a microtubule-associated protein essential for microtubule assembly and stability in neurons. The abnormal intracellular accumulation of tau aggregates is a major characteristic of brains from patients with Alzheimer’s disease (AD) and other tauopathies. In AD, the presence of neurofibrillary...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-01-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/25/2/831 |
| _version_ | 1797339828234223616 |
|---|---|
| author | Huahua Shi Yan Zhao |
| author_facet | Huahua Shi Yan Zhao |
| author_sort | Huahua Shi |
| collection | DOAJ |
| description | Tau is a microtubule-associated protein essential for microtubule assembly and stability in neurons. The abnormal intracellular accumulation of tau aggregates is a major characteristic of brains from patients with Alzheimer’s disease (AD) and other tauopathies. In AD, the presence of neurofibrillary tangles (NFTs), which is composed of hyperphosphorylated tau protein, is positively correlated with the severity of the cognitive decline. Evidence suggests that the accumulation and aggregation of tau cause synaptic dysfunction and neuronal degeneration. Thus, the prevention of abnormal tau phosphorylation and elimination of tau aggregates have been proposed as therapeutic strategies for AD. However, currently tau-targeting therapies for AD and other tauopathies are limited. A number of dietary bioactive compounds have been found to modulate the posttranslational modifications of tau, including phosphorylation, small ubiquitin-like modifier (SUMO) mediated modification (SUMOylation) and acetylation, as well as inhibit tau aggregation and/or promote tau degradation. The advantages of using these dietary components over synthetic substances in AD prevention and intervention are their safety and accessibility. This review summarizes the mechanisms leading to tau pathology in AD and highlights the effects of bioactive compounds on the hyperphosphorylation, aggregation and clearance of tau protein. The potential of using these bioactive compounds for AD prevention and intervention is also discussed. |
| first_indexed | 2024-03-08T09:54:02Z |
| format | Article |
| id | doaj.art-9e5d78ec82de4d029940ed54a58b6c83 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-08T09:54:02Z |
| publishDate | 2024-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-9e5d78ec82de4d029940ed54a58b6c832024-01-29T13:54:44ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672024-01-0125283110.3390/ijms25020831Modulation of Tau Pathology in Alzheimer’s Disease by Dietary Bioactive CompoundsHuahua Shi0Yan Zhao1Department of Bioengineering, Harbin Institute of Technology, Weihai 264209, ChinaDepartment of Bioengineering, Harbin Institute of Technology, Weihai 264209, ChinaTau is a microtubule-associated protein essential for microtubule assembly and stability in neurons. The abnormal intracellular accumulation of tau aggregates is a major characteristic of brains from patients with Alzheimer’s disease (AD) and other tauopathies. In AD, the presence of neurofibrillary tangles (NFTs), which is composed of hyperphosphorylated tau protein, is positively correlated with the severity of the cognitive decline. Evidence suggests that the accumulation and aggregation of tau cause synaptic dysfunction and neuronal degeneration. Thus, the prevention of abnormal tau phosphorylation and elimination of tau aggregates have been proposed as therapeutic strategies for AD. However, currently tau-targeting therapies for AD and other tauopathies are limited. A number of dietary bioactive compounds have been found to modulate the posttranslational modifications of tau, including phosphorylation, small ubiquitin-like modifier (SUMO) mediated modification (SUMOylation) and acetylation, as well as inhibit tau aggregation and/or promote tau degradation. The advantages of using these dietary components over synthetic substances in AD prevention and intervention are their safety and accessibility. This review summarizes the mechanisms leading to tau pathology in AD and highlights the effects of bioactive compounds on the hyperphosphorylation, aggregation and clearance of tau protein. The potential of using these bioactive compounds for AD prevention and intervention is also discussed.https://www.mdpi.com/1422-0067/25/2/831tau pathologyAlzheimer’s diseasedietary bioactive compounds |
| spellingShingle | Huahua Shi Yan Zhao Modulation of Tau Pathology in Alzheimer’s Disease by Dietary Bioactive Compounds International Journal of Molecular Sciences tau pathology Alzheimer’s disease dietary bioactive compounds |
| title | Modulation of Tau Pathology in Alzheimer’s Disease by Dietary Bioactive Compounds |
| title_full | Modulation of Tau Pathology in Alzheimer’s Disease by Dietary Bioactive Compounds |
| title_fullStr | Modulation of Tau Pathology in Alzheimer’s Disease by Dietary Bioactive Compounds |
| title_full_unstemmed | Modulation of Tau Pathology in Alzheimer’s Disease by Dietary Bioactive Compounds |
| title_short | Modulation of Tau Pathology in Alzheimer’s Disease by Dietary Bioactive Compounds |
| title_sort | modulation of tau pathology in alzheimer s disease by dietary bioactive compounds |
| topic | tau pathology Alzheimer’s disease dietary bioactive compounds |
| url | https://www.mdpi.com/1422-0067/25/2/831 |
| work_keys_str_mv | AT huahuashi modulationoftaupathologyinalzheimersdiseasebydietarybioactivecompounds AT yanzhao modulationoftaupathologyinalzheimersdiseasebydietarybioactivecompounds |